Role of NFKBIA & PTPN22 Genes Polymorphism in Acute Rejection

Status Completed

Clinical Trial Summary

Our study aimed at studying the impact of gene polymorphism of NFKBIA and PTPN22 genes on rejection episodes in liver transplant Egyptian recipients. Also assess patients' factors associated with graft rejection.

Clinical Trial Description

Liver transplantation is considered an effective therapy for severe liver disease, but graft dysfunction occurs in up to 13% of patients during the first year following transplantation, and rises to 35% after 5 years (Keeffe, 1999; Yu et al., 2001). Graft rejection is one of the major immunological complications following liver transplantation (Zheng et al., 2006). The nuclear factor of kappa light polypeptide gene enhancer B-cells inhibitor-alpha (NFKBIA) gene encodes a member of the nuclear factor-kappa-B inhibitor family. Polymorphisms in this gene might be associated with a susceptibility to acute rejection episodes following liver transplantation, as they may cause an increased activation level of the proinflammatory transcription factor nuclear factor of kappa light polypeptide gene enhancer in B-cells (NFκB). NFκB translocates to the nucleus and promotes the expression of a panel of genes (Karin and Ben-Neriah, 2000). Some of these, for example interleukin-2, interleukin-6, interleukin-12 or tumor necrosis factor-alpha, play an important role in the pathogenesis of allograft rejection and the activation of the immune system in general (Wei and Zheng, 2003). The protein tyrosine phosphatase nonreceptor 22 gene (PTPN22) encodes a strong T-cell regulator called lymphoid protein tyrosine phosphatase. Previously, PTPN22 was described as a susceptibility gene for autoimmunity because it contains single nucleotide polymorphisms (SNPs) associated with several autoimmune diseases. One SNP (rs2476601;1858G>A) has emerged as a particularly potent risk factor for autoimmunity. We address the question whether PTPN22 polymorphismsare also associated with acute rejection after liver transplantation. (Dullin et al., 2015). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06060808
Study type	Observational [Patient Registry]
Source	Helwan University
Contact
Status	Completed
Phase
Start date	March 15, 2021
Completion date	July 24, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01678937` - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents	N/A
Completed	`NCT03781414` - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension	Phase 2
Recruiting	`NCT02260375` - MSC Therapy in Liver Transplantation	Phase 1
Not yet recruiting	`NCT04514666` - VOCs in Kidney and Liver Transplants	N/A
Not yet recruiting	`NCT05335551` - TRU-IMMUNO: Optimizing Liver Immunosuppression
Completed	`NCT01745731` - Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration	Phase 2
Enrolling by invitation	`NCT05082077` - Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Completed	`NCT03874286` - The TOGETHER Project - Liver
Completed	`NCT04789213` - Mortality, Morbidity and Risk Factors of Liver Retransplantation
Recruiting	`NCT06400771` - Safety of DNP007 in Healthy Subjects	Phase 1
Recruiting	`NCT03603548` - Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial	N/A
Withdrawn	`NCT03315052` - Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects	Phase 4
Enrolling by invitation	`NCT05655273` - Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients	Phase 4
Active, not recruiting	`NCT05325073` - Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients	Phase 4
Recruiting	`NCT05707520` - Long-term Benefit of MPA in Liver Transplantation
Recruiting	`NCT04657562` - The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
Completed	`NCT01444079` - Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation	N/A
Active, not recruiting	`NCT06153641` - Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms